Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance

Author's Avatar
Jul 06, 2022

HAMBURG, GERMANY and FRANCE / ACCESSWIRE / July 6, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).